Jan Kamiński

Jan Kamiński

Auto-generated profile, based on publicly available information

Jan Kamiński

Independent Public Healthcare Facility in Garwolin, ul. Lubelska 50, 08-400 Garwolin, Poland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 August 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
KJKacper Jankowski
Kacper Jankowski
ADAnna Daniel
Anna Daniel
NKNatalia Kraciuk
Natalia Kraciuk
ABAlicja Bury
Alicja Bury
KBKarol Bartecki
Karol Bartecki
JKJan Kamiński
Jan Kamiński
Shift Work Sleep Disorder (SWSD) arises from misalignment between endogenous circadian rhythms and irregular work schedules, frequently resulting in poor sleep quality, increased fatigue, and heightened risk for cardiometabolic complications. Melatonin, a hormone produced in the pineal gland during darkness, is increasingly investigated for its role in addressing sleep difficulties among shift workers. This review synthesizes recent clinical evidence on the effectiveness of melatonin supplementation in improving sleep outcomes in night and rotating shift populations. The literature indicates potential benefits such as shorter sleep onset latency, increased total sleep time, and improved subjective sleep quality, alongside a strong safety record. Furthermore, melatonin’s influence on circadian rhythm regulation may provide additional metabolic and cardiovascular advantages. Nevertheless, inconsistencies in dosing, formulations, and trial designs limit the generalizability of current findings. Additional well-controlled clinical trials are needed to refine guidelines for melatonin use in occupational settings.

22 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
JDJulia Dolinkiewicz
Julia Dolinkiewicz
ASAgnieszka Szczerbinska
Agnieszka Szczerbinska
JKJan Kamiński
Jan Kamiński
SRSebastian Rurka
Sebastian Rurka
JBJulia Błoniecka
Julia Błoniecka
Aim: This review aims to explore the clinical relevance and therapeutic potential of monoclonal antibodies targeting the calcitonin gene-related peptide (CGRP) pathway in the preventive treatment of migraine. Emphasis is placed on their mechanism of action, efficacy, and safety as demonstrated in clinical trials, as well as on their practical implementation in routine care. By examining current evidence and real-world application, the review seeks to inform clinicians about the benefits and appropriate use of anti-CGRP monoclonal antibodies in patients with disabling migraine. Methods: We conducted a comprehensive literature search in April and May 2025 using the PubMed and Google Scholar databases. The search included peer-reviewed articles published between 2015 and 2025, with a focus on studies investigating monoclonal antibodies and geptans used in the treatment of migraine. We prioritized original research involving human subjects and excluded unpublished abstracts and conference proceedings. Only articles available in English and Polish were considered. Results: Recent studies confirm the sustained safety and effectiveness of all four CGRP monoclonal antibodies, supporting earlier access due to their good tolerability, reduced migraine frequency, and improved quality of life. Conclusions: We should increase the awareness among specialists about the effectiveness and safety of anti-CGRP monoclonal antibodies so that more patients have the opportunity to benefit from treatment.

23 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ABAlicja Bury
Alicja Bury
KBKarol Bartecki
Karol Bartecki
NKNatalia Kraciuk
Natalia Kraciuk
KKKatarzyna Krupa
Katarzyna Krupa
MPMałgorzata Piekarska-Kasperska
Małgorzata Piekarska-Kasperska
JKJan Kamiński
Jan Kamiński
Background. Recent years have demonstrated a considerable development of biological treatment of various autoimmune diseases. Lack of response and adverse effects of standard treatment have been pushing research to find new therapeutic agents with good efficacy and safety profile. Aim. This study reviews the current knowledge about the potential use of rituximab and dupilumab, two biological drugs, in the treatment of pemphigus vulgaris (PV), a debilitating skin disease. Material and methods. The article is based on research of clinical trials and case studies published on the PubMed and Cochrane databases using the following keywords: pemphigus vulgaris, rituximab, dupilumab. Results. The existing trials show that rituximab offers faster achievement of complete remission when compared to standard prednisone or mycophenolate mofetil treatment. It also reduces the cumulative prednisone dose followed by alleviation of steroid-related adverse events. Its effect is even visible on the molecular level, being the depletion of T-helper cells that play a crucial role in activation of anti-desmoglein antibody producing B-memory cells. The use of dupilumab in PV has only been documented in a few case studies, which still show that most patients with refractory PV benefited from dupilumab treatment by finally achieving and maintaining remission. Conclusions. Despite limited randomized studies and small patient groups, the results of the existing research suggest a promising role of biological agents in the future treatment of patients with pemphigus vulgaris.

15 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
ADAnna Daniel
Anna Daniel
MPMałgorzata Piekarska-Kasperska
Małgorzata Piekarska-Kasperska
KJKacper Jankowski
Kacper Jankowski
NKNatalia Kraciuk
Natalia Kraciuk
ABAlicja Bury
Alicja Bury
ESEwa Siedy-Florek
Ewa Siedy-Florek
Collagen supplementation is gaining popularity as a non-invasive method of supporting skin and joint health, fueled by both growing interest in anti-aging prevention and intense social media marketing efforts. This literature review covers clinical trials, regulatory analyses and societal aspects of collagen supplement consumption from 2015 to 2025. Results indicate moderate benefits of collagen in improving skin elasticity and joint function, although methodological limitations and product diversity make it difficult to draw firm conclusions. The article also highlights challenges related to accessibility, regulation and marketing ethics, especially in the context of influencer influence and consumer culture. The need to strengthen quality control, transparency of consumer information and professional education of health professionals was also pointed out. It was also suggested that international regulatory cooperation be strengthened and that further research be conducted on the safety and efficacy of supplementation. An interdisciplinary approach is crucial to ensure that consumers have access to safe products and reliable knowledge about collagen supplementation.

16 September 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
JBJulia Błoniecka
Julia Błoniecka
MPMałgorzata Piekarska-Kasperska
Małgorzata Piekarska-Kasperska
ADAnna Daniel
Anna Daniel
NKNatalia Kraciuk
Natalia Kraciuk
ABAlicja Bury
Alicja Bury
ASAgnieszka Szczerbinska
Agnieszka Szczerbinska
Background: Obstructive sleep apnea (OSA) is a common and clinically significant sleep disorder involving recurrent episodes of upper airway collapse during sleep. While pharyngeal obstruction is the primary mechanism, nasal obstruction may also increase airway resistance, promote mouth breathing, and contribute to sleep disruption and OSA severity. Objective: This narrative review aims to explore the impact of nasal obstruction on sleep quality and OSA severity, with a particular focus on pathophysiological mechanisms, clinical implications, and therapeutic relevance. Methods: Relevant literature published between 2000 and 2025 was identified through PubMed and Google Scholar using keywords such as “nasal obstruction”, “obstructive sleep apnea”, “nasal breathing”, “sleep disturbances”, “nasal surgery”, and “CPAP adherence”. Included studies were review articles, meta-analyses, and original clinical research involving adult populations. Results: Although nasal obstruction alone is rarely the primary cause of moderate to severe OSA, it may negatively influence sleep quality, promote mouth breathing, worsen upper airway collapsibility, and reduce adherence to CPAP therapy. Medical and surgical interventions aimed at improving nasal airflow have shown variable results in sleep-related outcomes. Conclusion: Nasal obstruction plays a significant yet complex role in OSA and sleep quality. Improving nasal patency may enhance patient-reported outcomes and facilitate more effective management of sleep-disordered breathing.

12 August 2025 in International Journal of Innovative Technologies in Social Science
Verified
Journal Article
Open access
PDF file
JKJan Kamiński
Jan Kamiński
SRSebastian Rurka
Sebastian Rurka
JDJulia Dolinkiewicz
Julia Dolinkiewicz
ASAgnieszka Szczerbinska
Agnieszka Szczerbinska
Sarcoidosis, also known as Besnier-Boeck-Schaumann disease, is a granulomatous disease of unknown etiology, with multisystemic manifestations that can affect performance and physical capacity in athletes. In most early-stage cases (stage I and II), the disease may resolve spontaneously without treatment. However, when sarcoidosis presents with atypical features such as splenomegaly, especially in physically active individuals or athletes, the prognosis may be more severe, potentially affecting exercise tolerance, recovery time, and return to training. A comprehensive diagnostic approach, combining clinical evaluation with radiological and histopathological confirmation, is essential. Splenomegaly has been associated with poorer outcomes in pulmonary sarcoidosis compared to favorable signs like erythema nodosum or arthritis. This article presents the case of a 22-year-old female patient, whose pulmonary sarcoidosis was complicated by splenomegaly. The case underlines the importance of early recognition in active individuals and timely intervention to improve prognosis and preserve physical performance. Methods: The authors reviewed literature from ScienceDirect, Cochrane Library, PubMed, Google Scholar, and UpToDate, focusing on sarcoidosis. The review emphasized the importance of combining clinical, radiological, and histopathological data for diagnosis, and noted that splenomegaly worsens prognosis in pulmonary sarcoidosis, while erythema nodosum and arthritis are linked to better outcomes. Conclusions: In physically active patients, especially athletes, atypical manifestations such as splenomegaly in pulmonary sarcoidosis may lead to significant performance decline and delay in returning to training. Early diagnosis and treatment are crucial not only for controlling disease progression but also for minimizing long-term impact on aerobic capacity, muscle strength, and recovery time. Clinicians should consider sarcoidosis in the differential diagnosis of unexplained fatigue, dyspnea, or decreased performance in young athletes.